⌘K
Loading ticker…
Corvus Pharmaceuticals, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Corvus Pharmaceuticals, Inc. (CRVS) has a 3-month relative strength percentile of 33 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 75. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.7%, relative volume 2.44×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
33 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CRVS is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $34M notional. Top 3 carry $88M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $34M |
| XBIState Street SPDR S&P Biotech ETF | 0.42% | $31M |
| IWMiShares Russell 2000 ETF | 0.03% | $23M |
| VXFVanguard Extended Market ETF | 0.01% | $12M |
| IWOiShares Russell 2000 Growth ETF | 0.06% | $8M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRVS Jan avg: 44.78% median: 6.91% win: 75% σ: 83.03% n: 4 2022-04-12 → 2026-05-29 | CRVS Feb avg: -8.85% median: -11.38% win: 25% σ: 15.24% n: 4 2022-04-12 → 2026-05-29 | CRVS Mar avg: -9.26% median: -20.21% win: 25% σ: 22.62% n: 4 2022-04-12 → 2026-05-29 | CRVS Apr avg: 1.08% median: 3.83% win: 60% σ: 15.68% n: 5 2022-04-12 → 2026-05-29 | CRVS May avg: 37.29% median: 5.29% win: 60% σ: 84.19% n: 5 2022-04-12 → 2026-05-29 | CRVS Jun avg: -9.62% median: -9.81% win: 25% σ: 13.36% n: 4 2022-04-12 → 2026-05-29 (current) | CRVS Jul avg: 8.15% median: 1.25% win: 50% σ: 22.93% n: 4 2022-04-12 → 2026-05-29 | CRVS Aug avg: 28.78% median: 23.29% win: 75% σ: 35.31% n: 4 2022-04-12 → 2026-05-29 | CRVS Sep avg: 0.13% median: 1.63% win: 50% σ: 27.73% n: 4 2022-04-12 → 2026-05-29 | CRVS Oct avg: 14.96% median: 7.51% win: 75% σ: 37.77% n: 4 2022-04-12 → 2026-05-29 | CRVS Nov avg: 14.95% median: 10.79% win: 100% σ: 14.39% n: 4 2022-04-12 → 2026-05-29 | CRVS Dec avg: -12.74% median: -12.42% win: 25% σ: 23.13% n: 4 2022-04-12 → 2026-05-29 |